menu
    • menu

    Company profile for NewAmsterdam Pharma

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, choleste...
    Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, cholesteryl ester transfer protein (CETP) inhibitor. The Company is investigating obicetrapib as the preferred LDL-c lowering therapy for patients who cannot be treated optimally with current available lipid-lowering therapy.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NewAmsterdam PharmaNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Gooimeer 2-35 1411 DC Naarden The Netherlands
    Telephone
    Telephone
    +31 (0) 35 206 2971
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.newamsterdampharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NewAmsterdam Issues Inducement Grants Under Nasdaq Rule
    NewAmsterdam Issues Inducement Grants Under Nasdaq Rule

    01 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/01/3286241/0/en/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html

    GLOBENEWSWIRE
    01 May 2026
    Share Share
    NewAmsterdam Pharma at 25th Needham Healthcare Event
    NewAmsterdam Pharma at 25th Needham Healthcare Event

    08 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/08/3270040/0/en/NewAmsterdam-Pharma-to-Present-at-the-25th-Annual-Needham-Virtual-Healthcare-Conference.html

    GLOBENEWSWIRE
    08 Apr 2026
    Share Share
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Rules
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Rules

    02 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/02/3267879/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    02 Apr 2026
    Share Share
    NewAmsterdam Pharma Presents 3 Abstracts at 2026 ACC
    NewAmsterdam Pharma Presents 3 Abstracts at 2026 ACC

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260336/0/en/NewAmsterdam-Pharma-Announces-Three-Presentations-at-the-2026-American-College-of-Cardiology-Annual-Scientific-Session.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    NewAmsterdam Pharma Grants Inducements Under Nasdaq Listing Rule
    NewAmsterdam Pharma Grants Inducements Under Nasdaq Listing Rule

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/06/3251302/0/en/NewAmsterdam-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    Newamsterdam Pharma Joins March Investor Conferences
    Newamsterdam Pharma Joins March Investor Conferences

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244537/0/en/NewAmsterdam-Pharma-to-Participate-at-Upcoming-Investor-Conferences-in-March.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search